Mon, May 6, 2013
Sun, May 5, 2013
Fri, May 3, 2013
Thu, May 2, 2013
Wed, May 1, 2013
Tue, April 30, 2013
Mon, April 29, 2013
Sun, April 28, 2013
Fri, April 26, 2013
Thu, April 25, 2013
Wed, April 24, 2013
Tue, April 23, 2013
Mon, April 22, 2013
Sun, April 21, 2013
Fri, April 19, 2013
Thu, April 18, 2013
Wed, April 17, 2013
Tue, April 16, 2013
Mon, April 15, 2013
Fri, April 12, 2013
Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013

Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference


//health-fitness.news-articles.net/content/2013/ .. t-12th-annual-needham-healthcare-conference.html
Published in Health and Fitness on Wednesday, April 24th 2013 at 13:15 GMT by Market Wire   Print publication without navigation


Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference -- CHAPEL HILL, N.C., April 24, 2013 /PRNewswire/ --

CHAPEL HILL, N.C., April 24, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: [ CEMP ]) today announced that Prabhavathi Fernandes , Ph.D., president and chief executive officer of Cempra, will present at the 12th Annual Needham Healthcare Conference at 1:40 p.m. EDT, Wednesday, May 1, at the Westin New York Grand Central Hotel in New York. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA™ (CEM-102 or fusidic acid) for the chronic, oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are in advanced clinical development; solithromycin in Phase 3 for CABP and TAKSTA™ (CEM-102) in Phase 2 for prosthetic joint infections. Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at [ www.cempra.com ].

Investor and Media Contacts:
Robert E. Flamm , Ph.D.
Russo Partners, LLC
(212) 845-4226
[ Robert.flamm@russopartnersllc.com ]

Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235
[ Andreas.marathis@russopartnersllc.com ]

SOURCE Cempra, Inc.



RELATED LINKS
[ http://www.cempra.com ]

Publication Contributing Sources